57. ROS1 and KRAS Mutated Lung Cancer

In this episode, the Nautilus reaches its final destination, where Michael and Josh pursue a deeper understanding of ROS1, and KRAS mutated lung cancer. ROS1 reflected less than 3% of non-small cell lung cancer, while KRAS is abundant and can reflect up to 25% of lung cancer patients. The challenge lies in the targets, with the only approved KRAS treatment sotorasib targeting a single KRASG12C mutation. Many, many more KRAS mutations exist in the wild. Michael uses his oxygen tank to discuss an integrated efficacy and safety analysis of entrectinib, and Josh breaks free of a shark and highlights the CodeBreaK 200 study.

Links to studies discussed in this episode (subscription may be required):

CodeBreaK 200: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00221-0/fulltext

Integrative Analysis: https://pubmed.ncbi.nlm.nih.gov/31838007/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.